Approximately how many boxes of erdafitinib are required per month?

Erdafitinib (Erdafitinib) is a targeted therapy drug mainly used to treat patients with locally advanced or metastatic urothelial carcinoma (UC; bladder cancer ) with FGFR gene mutations. The drug exerts anti-tumor effects by inhibiting the fibroblast growth factor receptor (FGFR) pathway. Therefore, before treatment with erdafitinib, the presence of FGFR gene alterations in the patient's tumor specimens must be confirmed. This makes its treatment plan more personalized and relies on genetic testing to screen suitable patients.

Early in treatment, the recommended starting dose of erdafitinib is 8 mg daily. Patients should take it orally once a day, and it is recommended to take it on an empty stomach. Depending on the patient's tolerance, especially blood phosphorus levels (because hyperphosphatemia is one of the common adverse reactions of erdafitinib), doctors may adjust the dose between days 14 and 21 of treatment, gradually increasing it to 9 mg daily. This dose adjustment needs to be done under close supervision by your doctor to ensure maximum efficacy while minimizing side effects.

As for the standard monthly dosage, according to the specifications currently sold on the market, erdafitinib usually comes in packaging formats such as5 mg × 28 tablets, 3 mg × 56 tablets, and 4 mg × 28 tablets. Taking the common specification of 5 mg × 28 tablets as an example, when the starting dose is 8 mg per day, you need to take about 30 tablets per month (8 mg × 30 days). Depending on the need for dose adjustment, the patient may need to increase the dose to 9mg later in the course of treatment. Then, after the dose adjustment, the patient's monthly dosage will be 28 tablets of 9mg. If other strengths are used, the dosage and number of boxes will be adjusted accordingly.

In general, the dosage plan of erdafitinib is not fixed, but is individually adjusted based on the patient's tolerance and treatment response. Patients should check their blood phosphorus levels regularly so that their dosage can be adjusted in a timely manner. At the same time, because erdafitinib has not been popularized in all hospitals or regions, the ways to obtain the drug and the price vary greatly. Patients should consider various factors when choosing drugs to ensure the continuity and stability of treatment.

Reference materials：https://www.balversa.com/